文献速递血脂与心血管预防冠心病

风险评工具在动脉粥样硬化性心血管疾病一级预防决策中的应用:AHA与ACC特别报告

Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology.
PubMed 文献 · Circulation · 2018-11-10

该特别报告总结了定量风险评估在一级预防中的证据基础,指出汇总队列方程广泛验证但可能在某些人群低估或高估风险。对于临界或中等风险患者,测量冠状动脉钙化可重新分类风险并优化他汀选择。报告还讨论了现有风险评分的优缺点及临床实施建议。

要点

  • 汇总队列方程广泛验证,但可能低估某些种族/族裔、低社会经济地位或慢性炎症病患者的风险。
  • 对临界或中等风险且决策不确定者,冠脉钙化测量可重新分类风险,优化他汀选择。
  • 风险评估应结合风险增强因素(如家族史)并促进医患共享决策。

核心结论

  • 定量风险评估是一级预防的关键步骤,汇总队列方程广泛验证但存在系统性低估或高估风险的局限。
  • 对临界或中等风险患者,冠脉钙化测量可重新分类风险并改善他汀治疗选择。

研究设计与样本

  • 美国心脏协会和美国心脏病学会的特别报告,总结定量风险评估的原理与证据基础。

主要发现

  • 汇总队列方程广泛验证,对美国一般临床人群广泛有用。
  • 可能系统性低估某些种族/族裔、低社会经济地位或慢性炎症病患者的风险。
  • 可能高估高社会经济地位或密切参与预防保健服务患者的风险。

关键数值与推荐

  • 当前美国血压和胆固醇预防指南推荐使用汇总队列方程启动医患共享决策。
  • 对临界或中等风险且决策不确定者,可测量冠状动脉钙化以重新分类风险。

临床怎么用

  • 使用汇总队列方程评估10年动脉粥样硬化性心血管疾病风险,识别高风险组以优化他汀和降压治疗。
  • 对临界或中等风险患者,结合风险增强因素讨论后仍不确定时,可考虑冠脉钙化测量。

局限性

  • 汇总队列方程可能在某些人群系统性低估或高估风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risk assessment is a critical step in the current approach to primary prevention of atherosclerotic cardiovascular disease. Knowledge of the 10-year risk for atherosclerotic cardiovascular disease identifies patients in higher-risk groups who are likely to have greater net benefit and lower number needed to treat for both statins and antihypertensive therapy. Current US prevention guidelines for blood pressure and cholesterol management recommend use of the pooled cohort equations to start a process of shared decision-making between clinicians and patients in primary prevention. The pooled cohort equations have been widely validated and are broadly useful for the general US clinical population. But, they may systematically underestimate risk in patients from certain racial/ethnic groups, those with lower socioeconomic status or with chronic inflammatory diseases, and overestimate risk in patients with higher socioeconomic status or who have been closely engaged with preventive healthcare services. If uncertainty remains for patients at borderline or intermediate risk, or if the patient is undecided after a patient-clinician discussion with consideration of risk enhancing factors (eg, family history), additional testing with measurement of coronary artery calcium can be useful to reclassify risk estimates and improve selection of patients for use or avoidance of statin therapy. This special report summarizes the rationale and evidence base for quantitative risk assessment, reviews strengths and limitations of existing risk scores, discusses approaches for refining individual risk estimates for patients, and provides practical advice regarding implementation of risk assessment and decision-making strategies in clinical practice.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2018. PMID: 30586766. doi:10.1161/CIR.0000000000000638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。